The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, highlights another step by Precisio Biotix to advance novel precision biological antibacterials.

The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, signifies a greater commitment to globalizing the Company's antibacterial science.

The announcement by Mark Engel, the Company's Chairman and CEO, signifies a greater commitment to the US market.

Delaware, US: July 2, 2023. The management team of Precisio Biotix Therapeutics, a company that develops novel precision biological antibacterial products, is proud to announce that effective July 2, 2023 it is a management owned and controlled company. 

Shanghai, Wuhan, November 12, 2021. Phagelux, Inc. is proud to announce the change of name of its Wuhan-based subsidiary to Lysigen (Chinese Name).

Montreal, Shanghai, Wuhan, November 4, 2021. Phagelux, Inc. is proud to announce the out-licensing of its staphylococcus lysin to Shanghai Pharmaceutical Holdings Co. (hereinafter referred to as “SPH”, 601607.SH; 2607.HK) for in vivo applications. This licensing agreement is limited to the greater China market.

Montreal, Shanghai, Wuhan, October 11, 2021. Phagelux, Inc. is proud to announce the trademark filing of LysiThru, our novel high through put screening system for rapidly developing lysins effective against both gram positive and gram negativebacteria.

Jan.16, 2020. Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.